HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First tuberculosis vaccine trial years begins

(Date:11/24/2014)... PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology Group ... Health’s Multiple Sclerosis Center. , A graduate of ... in Neurology at Albert Einstein Medical Center in Philadelphia ... Judith Jaffe Multiple Sclerosis Center at Weill Cornell Medical ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... CA (PRWEB) November 24, 2014 SafeHandles™ ... episode of Innovations with Ed Begley Jr, airing via ... was created to provide a passive, non-invasive, replaceable, and ... how SafeHandles™ incorporates custom-fit shrinkable sleeves and adhesives to ... , “At the core of SafeHandles is the ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Dr. Michael ... Fertility Center, recently appeared on NBC to discuss egg freezing ... freezing has been trending in the news recently, with new ... procedure for women. , “[The companies] see it ... are on a career hot path.” Says Dr. Kettel. , ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3
(Date:11/24/2014)... 24, 2014  Surgical Theater, LLC, announced today that ... th opening of Europe,s ... "C. Besta." The SuRgical Planner (SRP) and the Surgical ... event for their 3D navigation and augmented reality capabilities ... , Professor and Chair, Department of Neurosurgery at Mount ...
(Date:11/24/2014)...  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... board of directors and from his positions as chairman and ... serving as the company,s president and chief operating officer, will ... board of directors.  Gary Lyons , a member of ... Gower is expected to remain an employee until the end ...
(Date:11/24/2014)... Nov. 24, 2014  Pifflers United Chronic and ... the release of results of a study of ... the self-management of fibromyalgia pain. The results demonstrated ... pain, very significant clinically meaningful pain reduction can ... members with fibromyalgia used ActiPatch® for 7 days ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
Cached News: